In this article, we look at 10 Small Cap Stocks with Potential to Rise 1000 Percent.
Small-cap stocks have returned to the market’s risk conversation in 2026. The Russell 2000 was up 18.6% year-to-date through June 12, ahead of the Nasdaq, S&P 500, and Dow Jones Industrial Average, while MarketWatch reported that the index was trading near a record high in mid-June. The move has come even as the asset class remains exposed to higher borrowing costs. Reuters noted in May that smaller companies are especially vulnerable to yield spikes because many are still unprofitable and depend more heavily on future cash flows.
That risk profile is also why the upside cases can look extreme. Small-cap stocks are defined as those with market values between $300 million and $2 billion, and within that band, the most aggressive analyst targets are concentrated in biotechnology. The setup is not accidental. EY’s 2026 Biotech Beyond Borders report said biotech financing rose 11% to $68.5 billion in 2025, while Reuters reported that first-quarter 2026 biotech M&A reached $84 billion, nearly double the prior-year level. For speculative small-cap drug developers, clinical data, regulatory progress, partnerships, or takeover interest can sharply reset valuations, which is why some names still carry several hundred percent implied upside.
Methodology
For this article, we screened small-cap stocks with market capitalizations between $300 million and $2 billion. We then focused on companies with unusually high implied upside based on consensus analyst price targets, while avoiding stocks whose upside case depended solely on a single aggressive analyst estimate.
The final list was ranked by implied upside to consensus price target, from highest to lowest. Since exact 1,000% gains are speculative rather than measurable, the screen favored stocks with several hundred percent upside potential and broader analyst support.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. AtaiBeckley Inc. (NASDAQ:ATAI)
AtaiBeckley Inc. (NASDAQ:ATAI) is one of the small-cap stocks with potential to rise 1000 percent. The company’s investment case has become more concrete as BPL-003 moves closer to late-stage testing in treatment-resistant depression, rather than resting only on early psychedelic-drug enthusiasm. On June 8, it was reported that H.C. Wainwright reiterated a Buy rating and $25 price target on the stock after hosting AtaiBeckley management, with the firm saying BPL-003 remains the company’s core value driver as it prepares to initiate the Phase 3 ReConnection program in treatment-resistant depression.
That is important because AtaiBeckley is entering a more expensive but more valuation-relevant stage of development. In its May 12 business update, the company said BPL-003’s Phase 3 pivotal program remained on track to begin in Q2 2026, while VLS-01 Phase 2 topline data and BPL-003 Phase 2a Part 4 initial data were both expected in Q4 2026. The company also reported $209.9 million in cash, cash equivalents, and short-term securities as of March 31, 2026, and said its cash position was expected to fund operations into 2029, through anticipated BPL-003 Phase 3 topline readouts.
AtaiBeckley Inc. is a clinical-stage biotechnology company developing rapid-acting mental health treatments, including BPL-003 for treatment-resistant depression, VLS-01 for treatment-resistant depression, and EMP-01 for social anxiety disorder.
9. Neumora Therapeutics, Inc. (NASDAQ:NMRA)
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main near-term catalyst is navacaprant, an experimental depression treatment being tested in patients with major depressive disorder. On May 7, Neumora said two late-stage studies, KOASTAL-2 and KOASTAL-3, were fully enrolled in the first quarter of 2026, with more than 400 patients in each trial. The company expects to report combined top-line results from the two studies in the second quarter of 2026, making the update a major test of the stock’s bull case.
Neumora is also trying to build a broader brain-disease pipeline beyond navacaprant. The company said NMRA-511 remains on track to report data in the second half of 2026 from a study in agitation linked to Alzheimer’s disease, with a Phase 2 trial expected to begin in the first quarter of 2027. Another drug candidate, NMRA-898, is being tested in healthy volunteers and patients with stable schizophrenia, with Phase 1 data also expected in the second half of 2026. Neumora ended the first quarter with $147.1 million in cash and cash equivalents, which it expects to fund operations into the third quarter of 2027.
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for brain diseases, including depression, Alzheimer’s-related agitation, and schizophrenia.
8. Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the small-cap stocks with potential to rise 1000 percent. The company gave investors a new pipeline marker on May 21, when it reported initial Phase 1 clinical data for OP-3136, its KAT6 inhibitor, at the 2026 ASCO Annual Meeting. Olema said OP-3136 monotherapy was well-tolerated, with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events, while also showing evidence of anti-tumor activity across multiple solid tumor types.
The update adds an earlier-stage asset behind Olema’s main palazestrant program, where the more immediate valuation catalyst remains OPERA-01. In its May 12 first-quarter update, Olema said topline data from the Phase 3 OPERA-01 trial of palazestrant as a monotherapy in second- and third-line ER+/HER2- metastatic breast cancer are expected in fall 2026. The company also said its Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer continued to enroll patients. Olema ended the first quarter with $505.3 million in cash, cash equivalents, and marketable securities.
Olema Pharmaceuticals, Inc., operating as Olema Oncology, is a clinical-stage biopharmaceutical company developing targeted therapies for breast cancer and other cancers.
7. Allogene Therapeutics, Inc. (NASDAQ:ALLO)
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the small-cap stocks with potential to rise 1000 percent. The company’s 2026 setup now rests on whether it can turn its off-the-shelf CAR T platform into clinical evidence across both cancer and autoimmune disease. In its May 13 first-quarter update, Allogene said its pivotal Phase 2 ALPHA3 trial of cema-cel in first-line consolidation treatment for large B-cell lymphoma had completed an interim futility analysis and would continue without modification. The trial is designed to evaluate whether treating patients who remain at high risk of relapse after initial therapy can improve event-free survival versus observation.
The company also has a separate catalyst approaching in autoimmune disease. Allogene said initial data from the first dosing cohort of the Phase 1 RESOLUTION trial of ALLO-329 are expected in June 2026, including disease-related biomarkers, CAR T expansion, immune reconstitution, and early clinical outcomes. ALLO-329 is being studied across multiple autoimmune indications, including lupus, scleroderma, and inflammatory myositis. Allogene ended the first quarter with $266.9 million in cash, cash equivalents, and investments, and said its April public offering extended its cash runway into the first quarter of 2029.
Allogene Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic CAR T cell therapies for cancer and autoimmune diseases.
6. ProKidney Corp. (NASDAQ:PROK)
ProKidney Corp. (NASDAQ:PROK) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main story centers on rilparencel, its experimental cell therapy for patients with advanced chronic kidney disease and type 2 diabetes. On May 15, ProKidney said it remained on track to finish enrolling patients for an important part of its PROACT 1 late-stage trial in mid-2026, with key kidney-function results expected in the second quarter of 2027.
The trial is important because the FDA has already agreed that ProKidney can use a kidney-function measure called eGFR slope as the main basis for seeking accelerated approval. In simple terms, eGFR slope tracks how quickly a patient’s kidney function is worsening over time. ProKidney also pointed to earlier Phase 2 data from the REGEN-007 study, where one patient group showed a 4.6 mL/min/1.73m² improvement in annual kidney-function decline after treatment compared with the period before injection. The company ended the first quarter with $224.9 million in cash, cash equivalents, and marketable securities, which it expects to fund operations into mid-2027.
ProKidney Corp. is a late clinical-stage biotechnology company developing rilparencel, a cell therapy made from a patient’s own kidney cells, for advanced chronic kidney disease in patients with type 2 diabetes.
5. Cabaletta Bio, Inc. (NASDAQ:CABA)
Cabaletta Bio, Inc. (NASDAQ:CABA) is one of the small-cap stocks with potential to rise 1000 percent. The company’s 2026 story is focused on rese-cel, an experimental cell therapy being developed for autoimmune diseases, where the immune system mistakenly attacks the body. In its May 14 first-quarter update, Cabaletta said enrollment was progressing in a small registrational study of rese-cel in myositis, a group of rare autoimmune muscle diseases that can cause weakness and inflammation. If the study succeeds, Cabaletta expects it could support the company’s first planned application for FDA approval of rese-cel in myositis in 2027.
The update also gave investors a clearer timeline for upcoming clinical data. Cabaletta said it expects more results in the second half of 2026 from rese-cel studies in pemphigus vulgaris and lupus, along with data from patients receiving higher doses. The company also raised $150 million through a registered direct offering in May, with participation from investors including Bain Capital Life Sciences, Cormorant Asset Management, and Eli Lilly and Company. Cabaletta ended the first quarter with $116.6 million in cash, cash equivalents, and short-term investments, and said the offering extended its expected cash runway into mid-2027.
Cabaletta Bio, Inc. is a late-stage clinical biotechnology company developing engineered T-cell therapies for autoimmune diseases across rheumatology, neurology, and dermatology.
4. Autolus Therapeutics plc (NASDAQ:AUTL)
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the small-cap stocks with potential to rise 1000 percent. Unlike many biotech companies that are still waiting for their first approved product, Autolus already has a treatment on the market. Its drug AUCATZYL, also known as obe-cel, is approved for adults with a hard-to-treat form of blood cancer called relapsed or refractory B-cell acute lymphoblastic leukemia. In its May 14 first-quarter update, Autolus reported $26.2 million in AUCATZYL net product revenue, up from $9.0 million a year earlier, and said the business reached positive gross margin for the first time.
Autolus also kept its 2026 AUCATZYL revenue guidance at $120 million to $135 million, compared with $74 million in 2025. The company is trying to expand obe-cel beyond its first approved use, with studies in pediatric ALL, lupus nephritis, and progressive multiple sclerosis. On May 21, Autolus said an ASCO abstract from the FELIX study showed a 59% overall remission rate and a 42.6-month median duration of response in patients whose cancer had spread outside the bone marrow, a difficult-to-treat subgroup. Autolus ended the first quarter with $229.4 million in cash, cash equivalents, and marketable securities, enough to fund operations into the fourth quarter of 2027.
Autolus Therapeutics plc (NASDAQ:AUTL) is a commercial-stage biopharmaceutical company developing programmed T-cell therapies for cancer and autoimmune diseases.
3. Compass Therapeutics, Inc. (NASDAQ:CMPX)
Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main story is tovecimig, an experimental cancer treatment being developed for biliary tract cancer, which affects the bile ducts, gallbladder, or nearby digestive organs. In its May 5 first-quarter update, Compass said tovecimig had received FDA Orphan Drug Designation in April, a status meant for treatments targeting rare diseases. The company also said it planned to meet with the FDA ahead of a planned approval application later in 2026.
Compass is trying to move tovecimig toward regulators after a late-stage study showed stronger tumor response and longer disease control than chemotherapy alone. The company also said a Phase 1 study had begun for CTX-10726, another experimental cancer treatment, with initial data expected in the fourth quarter of 2026. Compass ended the first quarter with $195 million in cash and marketable securities, which it expects to fund operations into 2028. That gives the company time to push its lead cancer program through the next regulatory steps while also advancing earlier pipeline assets.
Compass Therapeutics, Inc. is a clinical-stage biotechnology company developing antibody-based treatments for cancer.
2. Altimmune, Inc. (NASDAQ:ALT)
Altimmune, Inc. (NASDAQ:ALT) is one of the small-cap stocks with potential to rise 1000 percent. The company’s lead drug candidate, pemvidutide, is being developed for MASH, a serious liver disease tied to fat buildup, inflammation, and scarring in the liver. On May 28, Altimmune said new 48-week data from its IMPACT Phase 2b study showed improvements in several health measures linked to MASH, including triglycerides, cholesterol, body weight, waist size, and blood pressure. At the 1.8 mg dose, patients with elevated baseline levels saw triglycerides fall 23.7% and total cholesterol fall 15.4% versus placebo.
Altimmune is trying to move pemvidutide into a larger Phase 3 study rather than leaving the program at mid-stage data. In its May 13 first-quarter update, the company said it expects to start the PERFORMA Phase 3 MASH trial in the second half of 2026, with 52-week data expected in 2029. The company is also testing pemvidutide in alcohol use disorder and alcohol-associated liver disease, with data or enrollment updates expected later in 2026. Altimmune had about $535 million in cash, cash equivalents, and short-term investments as of April 30, 2026, giving it a stronger balance sheet as the program moves into larger trials.
Altimmune, Inc. is a late clinical-stage biotechnology company developing pemvidutide for serious liver diseases, including MASH, alcohol use disorder, and alcohol-associated liver disease.
1. Silence Therapeutics plc (NASDAQ:SLN)
Silence Therapeutics plc (NASDAQ:SLN) is one of the small-cap stocks with potential to rise 1000 percent. The company’s lead story is divesiran, an experimental treatment for polycythemia vera, a rare blood cancer in which the body makes too many red blood cells. Patients often need repeated blood draws to lower red blood cell levels, and Silence is trying to reduce that treatment burden with a drug designed to turn down a disease-related gene signal.
On June 11, Silence presented follow-up Phase 1 data from the SANRECO study at the European Hematology Association 2026 Congress. In the six months before treatment, 21 patients needed 80 blood draws. During active treatment, that number fell to 5, and only 4 more blood draws were reported during the 16-week follow-up period after the final dose. Among 14 patients with longer follow-up, the median time to the first blood draw was 287 days.
The next test is larger. Silence said its Phase 2 SANRECO study remains on track for top-line results in August 2026. The company ended the first quarter with $70.1 million in cash, cash equivalents, and short-term investments.
Silence Therapeutics plc (NASDAQ:SLN) is a clinical-stage biotechnology company developing RNA-based medicines for blood disorders, cardiovascular disease, and rare diseases.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
